Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands

US8008488B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Hervé Geneste · Schifferstadt, DE
• Andreas Kling · Mannheim, DE
• Wilfried Braje · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE

Key dates

• Filing date: Mar 12, 2004
• Grant date: Aug 30, 2011
• Expiry date: Aug 11, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to pyrimidin 2-one compounds of general formula (I), in addition to the derivatives and tautomers of (I) and the physiologically acceptable salts of said compounds. In said formula, A represents linear or branched C3-C6 alkene, which can have a double bond or triple bond and/or a group Z, which is not adjacent to the nitrogen atom of the pyrimidinone ring and is selected from O, S, C(O), NR3, C(O)NR3, NR3C(O), OC(O) and C(O)O; B represents a group of the formula (II), in which X stands for CH2 or N and Y stands for CH2 or CH2CH2, or X—Y can also jointly represent C═CH, C═CH—CH2 or CH—CH═CH; R1 and R2 are defined as cited in the description and the claims; and Ar represents an optionally substituted aromatic group. The invention also relates to a pharmaceutical agent, containing at least one compound (I) and the tautomers, derivatives and/or acid addition salts of said compound, optionally together with physiologically acceptable carriers and/or auxiliary agents. The invention also relates to the use of compounds of formula (I), and their tautomers, derivatives and pharmacologically acceptable acid addition salts for producing a pharmaceutical agent for treatin…